-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, "O-drug" Navuliyu monoanti (commodity name: Odivo) combined chemotherapy in the first-line treatment of tumor expression PD-L1 and comprehensive score (CPS) of 5 metastatic stomach cancer, gastroesophageal connection (GEJ) cancer or esophageal adenocarcinoma Phase III clinical trials.
the trial data will be presented at a later medical conference.
is the fifth most common cancer in the world and the third leading cause of death.
, stomach cancer is the second-largest cancer after lung cancer, accounting for about half of all gastric cancer cases and deaths worldwide.
so far, gastric cancer immunotherapy drugs have O and K drugs.
In March this year, O-drug was officially approved by the China Drug Administration for the treatment of patients with advanced or relapsed stomach or gastroesophageal adenocarcinoma who had received two or more systemic treatment options in the past, and was the first immunotherapy approved in China for advanced stomach cancer.
, However, Navuliyu monoantigen has not yet been approved in the country esophageal cancer adaptation.
.